Mass Tort & Product Liability Lawsuits: Active Cases Directory (2026)
Independently fact-checked against primary sources (last audited September 14, 2026). · Law checked current as of August 8, 2026. · 48 primary sources cited on this page. How we verify our legal content

A mass tort is a single legal harm that affects many people at once, such as a drug, a chemical, a defective product, or a pattern of conduct that injures large numbers of consumers. Unlike a class action, each person keeps an individual case. This page is a living directory: it explains how mass torts and multidistrict litigation work, links our in-depth guides to the major active cases, lists the other active product-liability litigations we track, and notes the ones that are winding down or closed, with dates. It is general information and attorney advertising, not legal advice, and it is not a promise that anyone has a claim. Litigation status was last reviewed in August 2026.
What a mass tort is, and how it differs from a class action
A mass tort and a class action both involve many people harmed by the same thing, but they work differently. In a class action, one or a few named plaintiffs represent everyone, the cases are decided together, and class members typically share a single outcome and a common settlement formula. In a mass tort, each injured person files and keeps an individual lawsuit, because the injuries and damages differ too much from person to person to be treated identically. That structure matters for the people involved: a mass tort can account for the severity of each person's specific injury, while a class action is better suited to large numbers of small, nearly identical harms. Many product-liability cases, such as those over drugs, medical devices, and chemicals, proceed as mass torts for this reason.
What an MDL is and how it works
When thousands of similar federal lawsuits are filed across the country, the federal courts can consolidate them into a multidistrict litigation, or MDL, under the Judicial Panel on Multidistrict Litigation. One federal judge then manages all the pretrial work, including evidence-gathering and key rulings, which avoids duplicative proceedings and inconsistent decisions. An MDL is not a class action; each case remains separate and, if it is not resolved, can be sent back to its home court for trial. To gauge how juries view the evidence, the parties try a small set of representative cases called bellwether trials. The results, along with rulings on the science, often shape any later settlement framework. Most of the cases below are identified by an MDL number and the court that oversees it.
The active mass torts we cover in depth
The table links our informational guide for each case, with the general nature of the claims, where the federal litigation sits, and a short status. The guides explain the science and the regulatory record, the status as of a stated date, who may be involved, and how to think about your options. They do not promise that you qualify or that any amount is owed.

| Case | What it involves | Federal litigation | Status |
|---|---|---|---|
| Roundup (glyphosate) | Weedkiller use, alleged non-Hodgkin lymphoma | MDL 2741 (N.D. Cal.) | Proposed $7.25 billion class settlement (Missouri state court) awaiting final approval; the fairness hearing was held Sept 14, 2026, the court had not ruled as of Sept 17, 2026, and claims cannot be filed yet; SCOTUS ruled FIFRA preempts label-based claims (Jun 2026); on Oct 29, 2026 a St. Louis County, Mo. jury returned the first post-Durnell defense verdict, in Aretino v. Monsanto, rejecting three plaintiffs' design-defect, negligence and fraud claims |
| AFFF firefighting foam | PFAS exposure, alleged cancers and water contamination | MDL 2873 (D.S.C.) | Active |
| Talcum powder | Talc products, alleged ovarian cancer and mesothelioma | MDL 2738 (D.N.J.) | Active (largest MDL); $5.5 billion ovarian-talc settlement proposed Jul 2026, contingent on 95% claimant participation |
| Chemical hair relaxers | Hair straighteners, alleged uterine and ovarian cancer | MDL 3060 (N.D. Ill.) | Active |
| Rideshare assault | Uber and Lyft passenger sexual assault claims | MDL 3084 (N.D. Cal., Uber) | Active; the first two bellwether trials concluded in 2026 (a $8.5 million verdict in February and a $5,000 verdict in April, the latter under appeal), a third set for Oct 5, 2026 settled confidentially before opening statements and produced no verdict, the parties were briefing replenishment of the bellwether pool in mid Oct 2026 (Dkt. 7813, Oct 14, 2026), and there is no global settlement |
| Social media harm | Youth mental-health harms tied to platform design | MDL 3047 (N.D. Cal.) | Active; 1st bellwether settled before verdict (Jun 2026); on Aug 26, 2026 the court entered a consent judgment resolving the claims of a 51-attorney-general coalition, under which Meta is guaranteed to pay about $12.1 billion over ten years, rising to as much as $17.1 billion if contingency payments are triggered; it does not release the private personal-injury claims in the MDL, which the settlement agreement expressly carves out; a separate Oct 1, 2026 order set a pretrial schedule for the next two school-district bellwethers (Tucson Unified and Charleston County), with a first pretrial conference Nov 13, 2026 and trial to start Feb 8, 2027 |
| AI chatbot harm | Deaths and injuries alleged to be linked to AI chatbot design, including ChatGPT and Character.AI | Individual suits; the private OpenAI suits are coordinated in California state court (JCCP 5431) | Active; Garcia v. Character Technologies settled and was dismissed with prejudice on Oct 19, 2026; nine state attorneys general we confirmed have sued OpenAI in 2026 |
| Mesothelioma / asbestos | Asbestos exposure, mesothelioma and lung disease | Individual suits and asbestos bankruptcy trusts | Active (trusts) |
| Nursing home abuse | Abuse and neglect in long-term-care facilities | Individual state-law claims | Active |
| Ozempic / GLP-1 drugs | Semaglutide and similar drugs, alleged gastroparesis and GI injuries | MDL 3094 (E.D. Pa.) | Active |
| Depo-Provera | Injectable contraceptive, alleged intracranial meningioma | MDL 3140 (N.D. Fla.) | Settlement announced Jun 15, 2026 and a master settlement agreement signed Jul 21, 2026; the court appointed BrownGreer PLC as settlement administrator (Aug 5, 2026) and on Sep 4, 2026 appointed a qualified settlement fund administrator, a supplemental compensation fund allocation master, and a lien resolution administrator; terms are confidential, and because this MDL is not a class action no court fairness review applies; in Case Management Order No. 14 (Aug 10, 2026) the court recorded that the deadline for claimants to register for the Settlement Program is Nov 30, 2026, and in Case Management Order No. 12 (Jul 27, 2026) the parties represented that the claims process would begin to be completed and payments begin to roll out by the first quarter of 2027, which is the parties' projection rather than a court-ordered deadline |
| Camp Lejeune water | Contaminated base water (1953 to 1987), alleged cancers and illnesses | CLJA, E.D.N.C. | Filing window closed Aug 2024; a June 30, 2026 court order directs the plaintiffs' leadership group and the Justice Department to use best efforts toward a global settlement by Oct 30, 2026, reaffirmed unextended on Sept 29, 2026 in an order that also reappointed the leadership group to Oct 30, 2027 and found that progress toward a global settlement is being made; the first CLJA bench trials were reset on Sept 16, 2026, Mousser (kidney cancer) to Oct 26, 2026 and Fancher to Nov 9, 2026 |
| Suboxone film | Opioid-treatment film, alleged severe tooth decay | MDL 3092 (N.D. Ohio) | Active, with a bellwether protocol in effect under Second Amended Case Management Order No. 15 (Mar 27, 2026): a 500-plaintiff Records Collection Pool narrows to a 50-case Core Discovery Pool, then to a 15-case Trial Pool the parties are to select by Jan 29, 2027, and finally to 4 cases for trial. The protocol's proposed schedule contemplates a first trial setting in Mar 2028, a date the court has said it will reduce to an order later rather than one already fixed |
| Paraquat | Herbicide exposure, alleged Parkinson's disease | MDL 3004 (S.D. Ill.) | Active; settlement framework in place (terms confidential, not court-approved); opt-out cases in court-ordered discovery (Jun 2026) |
| Hernia mesh (Bard) | Polypropylene hernia mesh, alleged infection, adhesion, and revision surgery | MDL 2846 (S.D. Ohio) | Active; $1B+ settlement (2024) |
| Lyft passenger assault | Passengers alleging sexual assault by Lyft drivers | MDL 3171 (N.D. Cal.) | New (centralized Feb 2026) |
| GLP-1 vision loss (NAION) | Semaglutide drugs, alleged sudden vision loss (NAION) | MDL 3163 (E.D. Pa.) | Active pretrial litigation; centralized Dec 15, 2025, with 216 actions pending per the JPML's Sept 1, 2026 report; Case Management Order No. 12 (Jul 2, 2026) opened early discovery and motions on general causation and preemption or warning adequacy, with fact discovery targeted to close in Oct 2026 |
| Paragard IUD | Copper IUD, alleged to break or fracture on removal | MDL 2974 (N.D. Ga.) | Active; the first bellwether trial concluded Feb. 3, 2026 with a defense verdict, and in July 2026 the court entered an order scheduling the second bellwether trial to begin April 12, 2027 |
| Bard PowerPort | Implanted port catheter, alleged fracture and migration | MDL 3081 (D. Ariz.) | Active; the first trial (Apr 2026) ended in a split result, a defense verdict on two claims and a mistrial on two claims, per Becton Dickinson's Form 10-Q filed Aug 6, 2026, which does not say which claims went which way; the second bellwether, Divelbliss v. Bard Access Systems, No. 2:23-cv-01627 (D. Ariz.), produced a plaintiff's verdict, reported as $40 million in compensatory damages on design-defect and failure-to-warn claims with no punitive damages, and judgment was entered on the docket Sept 10, 2026. Case Management Order No. 42 set three further bellwether trials: Lattanzio v. Bard Access Systems, No. 24-cv-00680, for Oct 13 to Oct 30, 2026, Hicks, No. 23-cv-01703, for Dec 1 to Dec 18, 2026, and Sorensen, No. 23-cv-02557, for Feb 2 to Feb 19, 2027 |
| Cook IVC filters | Retrievable blood-clot filters, alleged fracture and migration | MDL 2570 (S.D. Ind.) | Active; reportedly nearing settlement |
Other active mass torts we track
These product-liability litigations are active as of September 2026 but do not yet have a full guide on this site. They are listed so the directory reflects the whole landscape, not only the cases we cover in depth. Each is identified by its MDL number and court so you can verify its current status through the federal courts. Inclusion here is informational and is not a statement that any person has a claim, and several of these are mature or declining rather than actively recruiting.
Prescription drugs and vaccines
| Case | What it involves | Federal litigation | Status |
|---|---|---|---|
| Proton-pump inhibitors (PPIs) | Nexium, Prilosec and Prevacid, alleged kidney injury and disease | MDL 2789 (D.N.J.) | Active |
| Valsartan / losartan / irbesartan | Blood-pressure (ARB) drugs contaminated with NDMA, alleged cancer | MDL 2875 (D.N.J.) | Active; three economic loss class settlements (Aurobindo-Irbesartan, Hetero-Valsartan, Vivimed-Losartan) had a June 2, 2026 claims deadline and a June 30, 2026 fairness hearing and received final approval in three separate orders filed July 6, 2026. They release overpayment claims only. Personal injury claims are excluded from those releases: the Aurobindo and Vivimed orders state those claims were being settled simultaneously and separately, while the Hetero order simply excludes personal injury and medical monitoring claims. The MDL as a whole remains active |
| Elmiron | Bladder-condition drug, alleged retinal/eye damage (maculopathy) | MDL 2973 (D.N.J.) | Resolving |
| Taxotere (docetaxel) | Chemotherapy drug, alleged permanent hair loss | MDL 2740 (E.D. La.) | Resolving; 81 of 15,572 actions still pending per the JPML's Sept 1, 2026 report |
| Taxotere eye injury (docetaxel) | Same drug, alleged tear-duct damage and excessive tearing (epiphora) | MDL 3023 (E.D. La., same judge; centralized Feb 1, 2022) | Active; 140 of 433 actions pending per the JPML's Sept 1, 2026 report |
| Tepezza | Thyroid-eye-disease infusion, alleged permanent hearing loss | MDL 3079 (N.D. Ill.) | Possible global settlement |
| Zostavax | Shingles vaccine, alleged injuries including the disease it should prevent | MDL 2848 (E.D. Pa.) | Wound down: pending actions fell from 826 of 2,665 total on July 1, 2026 to 0 of 2,664 total per the JPML's Oct 1, 2026 report, although the Panel still lists the docket among its active litigations. No global settlement has been reported, and the status of any remaining state-court claims is unconfirmed |
| Acetaminophen (Tylenol) / autism-ADHD | Prenatal acetaminophen use, alleged autism spectrum disorder and ADHD | MDL 3043 (S.D.N.Y.) | Revived, and now final at the circuit level: the 2nd Circuit vacated the exclusion of the plaintiffs' causation experts and reinstated more than 500 cases (Jul. 2026), and on Oct. 16, 2026 it denied the defense petition for panel rehearing or rehearing en banc. The reversal therefore stands; the documents reviewed do not show a Supreme Court petition on file, and the appeals court did not decide whether acetaminophen causes autism or ADHD |
| Dupixent (dupilumab) | Eczema/asthma biologic, alleged cutaneous T-cell lymphoma masked or worsened by the drug | MDL 3180 (D.N.J.) | New (centralized Jun 2026), growing fast |
| Tasigna (nilotinib) | Leukemia drug alleged to cause severe atherosclerotic and peripheral arterial occlusive disease, a risk plaintiffs say Novartis disclosed in Canada but not in the United States | MDL 3006 (M.D. Fla.) | Active |
| Fosamax (alendronate), No. II | Bone-density drug, alleged to cause femur fractures or similar bone injuries | MDL 2243 (D.N.J.) | Active and long-running; 562 of 1,294 total actions pending per the JPML's Sept 1, 2026 report. Claims in the MDL and in the parallel New Jersey Multicounty Litigation are being resolved under a confidential Master Settlement Agreement between Merck and the plaintiffs' Settlement Oversight Committee, which the New Jersey Superior Court recognized in an Order Aiding Private Settlement filed Aug 13, 2025 that appointed a claims and lien administrator, a mediator and a special facilitator |
| Chantix (varenicline), No. II | Smoking-cessation drug recalled by Pfizer in 2021 after the discovery of a nitrosamine impurity, N-nitroso-varenicline, described as a probable human carcinogen; these are economic-loss class claims rather than personal-injury claims | MDL 3050 (S.D.N.Y.) | Active but small; 17 of 17 total actions pending per the JPML's Sept 1, 2026 report |
| Gardasil (HPV vaccine) | Merck's HPV vaccine, alleged injuries and failure to warn | MDL 3036 (W.D.N.C.) | Open but largely resolved against the plaintiffs on procedural grounds: the Fourth Circuit held on Sept 4, 2025 that timely participation in the Vaccine Act's Court of Federal Claims petition process is a prerequisite to a tort suit against Merck, that a tort court may not revisit the Vaccine Act process's own timeliness finding, and affirmed dismissal. The Supreme Court denied certiorari on March 30, 2026 (Needham v. Merck, No. 25-924), leaving that ruling in place. Pending actions fell from 129 on June 1, 2026 to 6 of 258 total, still 6 of 258 as of Oct 1, 2026. Separately, Merck told investors in its Form 10-Q for the quarter ended June 30, 2026 that the conditions of its proposed October 2025 settlement have been met and that the agreement is now final, resolving the bulk of all pending Gardasil product liability claims in the U.S., with fewer than 15 product liability cases pending outside the U.S. |
Medical devices and implants
| Case | What it involves | Federal litigation | Status |
|---|---|---|---|
| Covidien hernia mesh | Covidien/Medtronic hernia mesh, alleged similar mesh-failure injuries | MDL 3029 (D. Mass.) | Active; the first bellwether trial returned an $88 million plaintiffs' verdict (Aug. 2026), which is subject to pending post-trial motions; no global settlement |
| Exactech implants | Knee, hip and ankle implants, alleged early failure requiring revision | MDL 3044 (E.D.N.Y.) | Stayed since Nov 2024; Ch. 11 plan confirmed Sept 2025 channels injury claims into a settlement trust whose compensation process is still being finalized |
| Allergan BIOCELL implants | Textured breast implants, alleged BIA-ALCL (a rare lymphoma) | MDL 2921 (D.N.J.) | Partly resolving; AbbVie reported in June 2026 an agreement to resolve substantially all US ALCL lawsuits, while about 1,300 other suits remain coordinated in the MDL, about 475 in state courts, and about 1,080 abroad |
| Bair Hugger | Forced-air surgical warming blankets, alleged deep-joint infections | MDL 2666 (D. Minn.) | Active |
| AngioDynamics / Navilyst port catheters | Implanted port catheter devices (a different manufacturer than Bard PowerPort), alleged fracture and embolization | MDL 3125 (S.D. Cal.) | Active, 350+ cases |
| Boston Scientific spinal cord stimulators | Implanted spinal cord stimulator devices, alleged inadequate clinical evaluation and device-performance injuries | MDL 3181 (C.D. Cal.) | New (centralized Jun 2026) |
| Abbott spinal cord stimulators | Implanted spinal cord stimulator devices made by Abbott, alleged misuse of the FDA premarket-approval supplement process to introduce modified devices, failure to warn, and sales representatives programming implanted devices without a physician present | MDL 3194 (N.D. Ill.) | New (centralized Oct. 2, 2026); 15 actions in 6 districts at centralization, assigned to Judge Lindsay C. Jenkins |
| Nevro spinal cord stimulators | Implanted spinal cord stimulator devices made by Nevro, alleged cumulative design changes pushed through premarket-approval supplements without disclosure, reporting and labeling failures, and sales representatives adjusting implanted devices | MDL 3195 (N.D. Cal.) | New (centralized Oct. 2, 2026); 17 actions in 6 districts at centralization, assigned to Judge Haywood S. Gilliam Jr. |
| Cartiva synthetic cartilage implant | Hydrogel big-toe implant (Stryker), alleged premature failure requiring revision surgery after a 2024 recall | MDL 3172 (E.D. Ark.) | New (centralized Feb 2026), small |
| Stryker LFIT V40 femoral heads | Cobalt-chromium LFIT Anatomic V40 femoral heads used in hip replacement, alleged to fail to lock fully onto the stem at the stem-head taper junction ("taper lock failure") and to corrode at that junction when paired with certain femoral stems, leading to implant failure and revision surgery; Stryker voluntarily recalled certain lots manufactured before March 2011 in August 2016 | MDL 2768 (D. Mass.) | Active but mature; 47 of 1,240 total actions pending per the JPML's Oct. 1, 2026 report, so the great majority of cases ever filed in this docket have already closed |
The three spinal cord stimulator dockets above are deliberately separate. The Judicial Panel on Multidistrict Litigation declined to centralize the SCS cases industry wide or to send the Abbott and Nevro cases to the judge already handling the Boston Scientific MDL, reasoning that the cases against different manufacturers will share preemption briefing but little else factually. A claim therefore belongs to the docket for the manufacturer of the device that was implanted.
Consumer and infant products
| Case | What it involves | Federal litigation | Status |
|---|---|---|---|
| Preterm infant formula (NEC) | Cow-milk-based premature-infant formula, alleged necrotizing enterocolitis | MDL 3026 (N.D. Ill.) | Active; Abbott agreed on Aug 20, 2026 to pay about $670 million to resolve the Gill verdict and NEC claims for roughly 2,000 more infants, and says about 1,700 suits covering roughly 12,700 infants remain pending; co-defendant Mead Johnson won a full defense verdict on all claims in the first federal bellwether tried against it (Inman v. Mead Johnson), jury verdict Aug 31, 2026 and judgment entered Sept 1, 2026, with post-trial deadlines not yet expired |
| Toxic baby food (heavy metals) | Baby food alleged to contain heavy metals, alleged autism/ADHD | MDL 3101 (N.D. Cal.) | Active but severely weakened; a Feb 27, 2026 order excluded the plaintiffs' exposure calculations and the causation opinions of their epidemiology and toxicology experts, though one expert was allowed, and the MDL remains open with 483 actions pending as of Sept 1, 2026 |
| ByHeart infant formula | Recalled infant formula, alleged botulism contamination | MDL 3178 (S.D.N.Y.) | New (just centralized) |
| Recalled Abbott infant formula (2022 Sturgis recall) | Powdered infant formula made at Abbott's Sturgis, Michigan plant and recalled in 2022 over alleged bacterial contamination; combines economic-loss class claims and personal-injury claims | MDL 3037 (N.D. Ill.) | Active but small; 14 of 141 total actions were still pending as of the JPML's Sept. 1, 2026 report. This is a separate litigation from the preterm infant formula (NEC) MDL 3026 above |
| Onewheel self-balancing electric skateboards | Boards alleged to shut off unexpectedly mid-ride, causing the front to dig into the ground (a "nosedive") and throw the rider at speeds as high as 20 miles per hour | MDL 3087 (N.D. Cal.) | Active; the personal-injury and wrongful-death track reached a settlement in principle announced Dec 18, 2025, and the court appointed Epiq as qualified settlement fund and lien administrator (Apr 7, 2026) and Robert A. Black as settlement special master (May 7, 2026); the separate purchaser economic-loss class track was still unresolved as of the last public docket entry describing it (Jun 29, 2026) |
| Generac PWRcell solar power systems | Residential solar storage systems whose SnapRS rapid-shutdown components are alleged to fail and leave an entire solar array inoperable, despite a 25-year component warranty; these are economic-loss class claims | MDL 3078 (E.D. Wis.) | Settled; 8 of 9 total actions were pending per the JPML's Sept 1, 2026 report, and the court held a final approval hearing on Oct 21, 2026 and entered an Order and Judgment granting final approval of the classwide $15 million settlement on Oct 22, 2026 before Judge Lynn Adelman (E.D. Wis.), together with an order on class counsel's fees and costs the same day. The claim-filing deadline passed on Aug 24, 2026, and no notice of appeal was posted on the administrator's court documents page as of Nov 5, 2026; payment amounts and timing remain subject to completion of the settlement process |
| MONAT hair care products | Hair care products advertised as promoting hair stability and growth, alleged instead to cause significant hair loss or thinning along with itching, scalp irritation, sores and cystic acne | MDL 2841 (S.D. Fla.) | Active but small; 13 of 13 total actions pending per the JPML's Oct. 1, 2026 report |
Automotive and vehicle products
| Case | What it involves | Federal litigation | Status |
|---|---|---|---|
| Kia and Hyundai vehicle theft | 2011 to 2022 Kia and 2015 to 2022 Hyundai vehicles with traditional insert-and-turn steel key ignitions, alleged to be defective because they lack engine immobilizer technology and are unusually easy to steal | MDL 3052 (C.D. Cal.) | Active; 100 of 117 total actions pending per the JPML's Sept 1, 2026 report |
| ARC airbag inflators | Airbag inflators alleged to be prone to rupture and to disperse shrapnel into the passenger compartment, with recalls issued to date alleged to be inadequate | MDL 3051 (N.D. Ga.) | Active; 24 of 24 total actions pending per the JPML's Sept 1, 2026 report |
| Chrysler Pacifica fire recall | Model year 2017 and 2018 Pacifica plug-in hybrids alleged to be prone to fire, with the February 2022 voluntary recall notice alleged to be inadequate | MDL 3040 (E.D. Mich.) | Active but small; 11 of 13 total actions pending per the JPML's Sept 1, 2026 report |
| ZF-TRW airbag control units | Airbag control units in vehicles from several automakers, alleged to use an application specific integrated circuit vulnerable to an electrical overstress condition that can keep the airbag from deploying in a crash; this is a different alleged defect from the ARC inflator cases above, which concern inflators rupturing rather than airbags failing to deploy | MDL 2905 (C.D. Cal.) | Active; 28 of 28 total actions pending per the JPML's Oct. 1, 2026 report |
Chemical and occupational exposure
| Case | What it involves | Federal litigation | Status |
|---|---|---|---|
| Firefighter turnout gear (non-AFFF PFAS) | Turnout (bunker) gear alleged to contain PFAS, claimed to expose firefighters through skin contact and inhalation; separate from the AFFF foam litigation | MDL 3191 (D. Minn.) | New (centralized Aug. 2026); on Sept. 12, 2026 a group of 28 municipalities and fire departments filed a complaint in the MDL adding federal RICO claims to the existing product-liability and consumer-protection claims, seeking economic losses rather than personal injury |
Rideshare and platform safety
| Case | What it involves | Federal litigation | Status |
|---|---|---|---|
| Roblox child exploitation | Gaming platform alleged to enable grooming and exploitation of minors | MDL 3166 (N.D. Cal.) | New (growing); the MDL had 182 actions pending as of Sept 1, 2026. Roblox has separately settled state attorney general child safety claims with five states: Alabama, West Virginia and Nevada in April 2026, then Mississippi and South Dakota in July 2026. Its Form 10-Q for the quarter ended June 30, 2026 reports $91 million accrued in the first half of 2026 for settlement agreements and settlement discussions, and lists suits still pending as of July 30, 2026 from ten further states (Arkansas, Florida, Indiana, Iowa, Kentucky, Louisiana, Nebraska, Oklahoma, Tennessee and Texas) plus Los Angeles County, California |
Tracking devices and stalking-enabled harm
| Case | What it involves | Federal litigation | Status |
|---|---|---|---|
| Apple AirTag stalking | Bluetooth tracking tags, alleged inadequate anti-stalking safeguards that let another person hide a tag in a victim's car, belongings or a child's belongings and track their movements covertly | MDL 3199 (N.D. Cal.) | New (centralized Oct. 2, 2026); 17 actions in 13 districts at centralization, assigned to Judge Noël Wise |
This litigation is a product-liability case about the design of a consumer tracking device rather than a wiretapping or surveillance case, and it turns on what Apple knew about the risk of misuse when it released the AirTag, whether safer designs were feasible, and how it responded to reports of stalking. Separately from any civil litigation, planting a tracker on someone else's vehicle or property is itself regulated by state law; see our GPS tracking laws by state guide.
A separate, very large set of cases, the National Prescription Opiate Litigation (MDL 2804, N.D. Ohio), coordinates claims brought largely by state and local governments over the opioid epidemic. It is mentioned here for completeness, but it is primarily a governmental matter rather than the kind of individual personal-injury case the rest of this directory describes.
Mass torts that are winding down, settled, or closed
Mass torts do not last forever. Some reach a global settlement and stop accepting new clients, some have their filing window close by law, and some are dismissed when a court excludes the scientific evidence. People still search for these by name, so this section records where each one stands and the key dates, as of August 2026. A litigation appearing here generally means it is no longer actively recruiting, but deadlines and appeals can still matter, so treat the dates as a starting point and confirm current status before relying on them.
| Case | What it involved | Status and key dates |
|---|---|---|
| 3M Combat Arms earplugs | Military-issue earplugs, alleged hearing loss and tinnitus among service members | Settled, still paying out. 3M agreed in August 2023 to pay up to $6.0 billion; the administrator reported about $3.09 billion issued to claimants as of September 2026, roughly half the total, including an $800 million tranche funded on September 15, 2026, with another $150 million scheduled for December 1, 2026 and deferred payments continuing through 2029. Registration is closed and it is no longer recruiting. This was the largest mass tort in US history by case count. |
| Juul / e-cigarettes | Vaping products alleged to be marketed to minors and to cause nicotine addiction and injury | Largely resolved. Juul reached a series of settlements in 2023, including roughly $1.2 billion with school districts and government entities and a $462 million deal with several state attorneys general. No longer recruiting. |
| Philips CPAP and ventilator recall | Recalled sleep-apnea machines with degrading foam, alleged respiratory injury and cancer | Settled and funded. Philips agreed in 2024 to a roughly $1.1 billion package covering personal-injury claims and a medical-monitoring class, on top of an earlier economic-loss settlement. The MDL court granted final approval of the medical-monitoring class settlement on December 5, 2024, and Philips has reported that both settlements became final in January 2025 and were paid in full during the first half of 2025. The federal MDL (No. 3014, W.D. Pa.) is still listed as active by the federal courts. |
| Zantac (ranitidine) | Heartburn drug alleged to break down into the carcinogen NDMA, claimed to cause cancer | Contested, not over. A December 2022 ruling excluding the plaintiffs' general-causation experts led to the dismissal of about 14,000 federal cases, but those dismissals are on appeal to the Eleventh Circuit, argued October 10, 2025 and still undecided. The JPML's September 1, 2026 report still lists the MDL as an active docket with 847 of 15,018 actions pending. GSK separately agreed in October 2024 to pay up to $2.2 billion to resolve about 80,000 state-court cases, which does not resolve the federal MDL. Delaware's remaining state cases were dismissed on summary judgment in April 2026 and are also on appeal. |
| Johnson & Johnson aerosol sunscreen (benzene) | Neutrogena and Aveeno aerosol sunscreens alleged to contain benzene, a known carcinogen, traced to the isobutane propellant; these were purchaser claims for refunds, vouchers and testing reforms rather than personal-injury claims | Settlement approval vacated on appeal, docket open but empty. The district court approved a class settlement, and on June 20, 2024 the Eleventh Circuit vacated that approval and remanded (Nos. 23-11319 and 23-11541), directing the court to apply Drazen v. Pinto, 101 F.4th 1223 (11th Cir. 2024), which treats vouchers redeemable against any of a company's products as coupon relief under the Class Action Fairness Act, and to decide whether any named plaintiff has standing to seek the prospective injunctive relief the deal promised, which would have required purging the implicated propellant inventory and adding benzene testing protocols. The JPML's October 1, 2026 report still lists MDL 3015 (S.D. Fla., Judge Raag Singhal, master docket 0:21-md-3015) among its active litigations with no closing date, but shows 0 of 16 historical actions now pending. What has happened on remand could not be confirmed from a public primary source, so there is no confirmed claims process to join and no claim deadline to rely on; check the docket before acting on this entry. |
| Bard IVC filters | Blood-clot filters alleged to fracture, migrate, or perforate the vena cava | Closed for Bard. The C.R. Bard IVC-filter litigation closed in July 2024 through confidential settlements. A separate litigation over Cook Medical filters remains active and is listed above. |
| Essure | Permanent birth-control implant alleged to cause chronic pain and organ injury | Resolved. Bayer announced a roughly $1.6 billion settlement in August 2020 resolving the large majority of claims, and the device was pulled from the US market in 2018. No longer recruiting. |
| Transvaginal / pelvic mesh | Surgical mesh for prolapse and incontinence, alleged erosion, chronic pain, and organ damage | Largely closed. The seven federal pelvic-mesh MDLs wound down by about 2020 after years of settlements and verdicts totaling billions of dollars. Only scattered individual or state cases remain. |
Who may be involved
The people involved in a mass tort are generally those who used the product, were exposed to the substance, or experienced the conduct at issue, and who later developed a related injury or condition. The specifics differ by case: a Roundup claim centers on herbicide use and a non-Hodgkin lymphoma diagnosis, an AFFF claim on firefighting-foam exposure and certain cancers, a nursing-home claim on harm to a specific resident. Family members sometimes bring claims on behalf of someone who has died or cannot act for themselves. Whether any individual situation fits a particular litigation is a fact-specific question that only a licensed attorney can evaluate after reviewing the details, the medical records, and the applicable state law.
Deadlines: statutes of limitations vary by state
Every claim is subject to a statute of limitations, the legal deadline to file, and in mass torts these deadlines are easy to misjudge. They vary by state and by the type of claim, they can be shorter for wrongful death than for personal injury, and many start running not when the exposure happened but when the injury was, or reasonably should have been, discovered. Some litigations also have their own court-set deadlines or registration requirements. Because missing the deadline usually bars the claim permanently, the timing question is one of the first things to check, and it is one reason people speak with an attorney sooner rather than later. This overview cannot tell you your deadline.
How mass-tort claims and fees work
Mass-tort cases are almost always handled on a contingency-fee basis. That means you do not pay an attorney fee up front; the attorney is paid a percentage of any recovery, and if there is no recovery there is generally no fee, though clients may still be responsible for certain case costs depending on the agreement. A free initial consultation is standard and does not create an attorney-client relationship by itself. Be cautious of any source that guarantees a result or a dollar amount, because no honest attorney can promise either; outcomes depend on the evidence, the science, the specific injury, and the court.

How mass torts get resolved
Most mass torts do not end in thousands of separate trials. After the science is tested and a few bellwether cases are tried, the parties often negotiate a global settlement that resolves large groups of cases at once. These settlements are usually structured rather than a single equal payment: a settlement grid or points system assigns value based on factors like the specific injury, its severity, the strength of the proof of exposure or use, the claimant's age, and other circumstances. A claimant with a serious, well-documented injury may be placed in a higher tier than someone with a minor or poorly documented one, and some claims are rejected entirely. Settlement participation is often voluntary, and claimants generally decide, with their attorney, whether to accept an offer or keep litigating. Because the framework can take years to negotiate and administer, a mass tort is typically a slow process, not a quick payout.
Bellwether trials and why they matter
A bellwether trial is a test case. From the large pool of filed cases, the parties and the judge select a representative sample to try first. These trials are not binding on the other cases, but they are enormously influential: they show how real juries react to the evidence and the science, what damages juries award, and how the key legal rulings hold up. A string of large plaintiff verdicts tends to push defendants toward settlement and can raise the value of the remaining cases, while defense verdicts can do the opposite. For anyone following a mass tort, the bellwether results, together with the judge's rulings on whether the scientific evidence is admissible, are the clearest signals of where the litigation is heading. They are also why the status of a mass tort can shift quickly, which is why every guide here dates its status.
What compensation in a mass tort can cover
When a mass-tort claim succeeds, by settlement or verdict, compensation generally falls into recognized categories of damages, though no amount is ever guaranteed. Economic damages cover measurable losses such as medical bills, the cost of future care, and lost wages or earning capacity. Non-economic damages address pain and suffering, disfigurement, and loss of quality of life. In cases involving a death, surviving family members may recover wrongful-death damages. A small number of cases also involve punitive damages, meant to punish especially reckless conduct and limited by law. How much any individual receives depends on the injury, the evidence, the settlement framework or the jury, and the applicable state law. Advertisements that promise a specific sum are misleading, because the value of a real claim cannot be known in advance.

How long a mass tort takes
Mass torts move on a scale of years, not months. After cases are filed and consolidated, the pretrial phase, where evidence is exchanged and the science is litigated, commonly takes a year or more on its own. Bellwether trials follow, and only then do serious settlement talks usually begin. Even after a settlement framework is announced, claimants must document their claims and awards are administered in waves, which adds more time. For someone deciding whether to pursue a claim, the practical points are that there is rarely a fast payout, that the deadline to file can arrive long before the litigation resolves, and that staying in contact with counsel matters because claim deadlines and documentation requests carry their own cutoffs.
Avoiding mass-tort advertising traps
Mass torts attract heavy advertising, and not all of it is trustworthy. Be cautious of any ad or call that guarantees you qualify, promises a specific dollar amount, pressures you to sign immediately, or asks for money upfront, because legitimate mass-tort representation is contingency-based and no one can promise a result. Unsolicited robocalls and texts claiming you are owed money are a common and often unlawful tactic, and some are outright scams that harvest personal information. A safer path is to speak directly with a licensed attorney, confirm they are licensed in a relevant state, and read any agreement before signing. You are never obligated to use the first firm that contacts you, and you can change your mind before you sign a representation agreement.
How this directory stays current
New product, drug, and chemical litigations emerge regularly, and others wind down as they settle or are dismissed, so any list is a snapshot. We review this directory against the federal courts' pending-MDL list on a recurring basis and update the entries, which is why each status is dated. Some mass torts are created by special legislation rather than ordinary litigation, such as the federal Camp Lejeune Justice Act, which opened a defined window for claims tied to contaminated water at the North Carolina base. Because a litigation's status, and even whether it survives early legal challenges to the science, can change quickly, the safest approach for any tort is to check current, authoritative sources, the federal courts and the relevant agency, rather than rely on advertising.
State-court mass torts, not just federal MDLs
Not every mass tort lives in a federal MDL. States have their own consolidation tools, such as California's Judicial Council Coordination Proceedings and similar mechanisms elsewhere, that group related cases before a single state judge. Many large litigations proceed on parallel tracks, with some cases in the federal MDL and others coordinated in state court, and the choice of forum can affect timing, procedure, and which law applies. For an individual, which track a case belongs in is a strategic question for an attorney, and it is one reason the same product can be the subject of both federal and state proceedings at the same time.

What to gather before talking to an attorney
If you decide to speak with an attorney, a consultation goes faster and is more useful if you bring the basics. Helpful items include the product or its packaging, lot numbers, or other proof of the exposure; your medical records and the diagnosis, with dates; a timeline of when and how long you used the product or were exposed; and any documentation of treatment and costs. For a claim on behalf of someone who has died, the relevant records and proof of your relationship matter. You do not need to have everything to start, and an attorney can help obtain records, but a clear timeline of dates is especially important because it bears directly on the filing deadline.
Harmed by a product or exposure? Speak with an attorney about your options
If you or a loved one may have been harmed, you can speak with an attorney about your legal options at no cost. Whether you have a claim depends on the specific facts. This is attorney advertising, not a guarantee that you qualify or of any particular outcome.
Frequently Asked Questions
What is the difference between a mass tort and a class action?
In a class action, many people are represented together and share one outcome. In a mass tort, each injured person keeps an individual lawsuit, often coordinated in one court (an MDL), so the result can reflect each person's specific injury.
What is an MDL?
A multidistrict litigation consolidates many similar federal lawsuits before a single judge for pretrial proceedings, including bellwether trials. It is not a class action; each case stays separate and can return to its home court for trial.
How do I know if I qualify for a mass tort claim?
There is no way to know from a website. Whether you may have a claim depends on the product or exposure, your injury, the timing, and your state's law. A licensed attorney can evaluate the specific facts, usually at no cost.
How much is a mass tort case worth?
There is no guaranteed amount, and any figure you see advertised is not a promise. Recoveries depend on the evidence, the injury, and the court. A verdict or settlement in one case does not set the value of another.
Is there a deadline to file?
Yes. Statutes of limitations vary by state and by claim type, and some run from when an injury is discovered. Missing the deadline usually bars the claim permanently, so it is worth checking early.
What happens to a mass tort when it settles or closes?
When a global settlement is reached or a court closes a litigation, firms usually stop taking new clients and remaining deadlines or appeals play out. People can still research closed torts, which is why this directory keeps dated status notes, but a closed or dismissed case generally is not a current claim opportunity.
Updates
Added the outcome of the first Roundup trial held after Monsanto Co. v. Durnell: on October 29, 2026 a St. Louis County, Missouri jury returned a unanimous defense verdict for Monsanto in Theresa Aretino, et al. v. Monsanto Company, rejecting three plaintiffs' design-defect, negligence, and fraud claims.
Updated the Generac PWRcell row: the court granted final approval of the $15 million classwide settlement on October 22, 2026, so the row no longer describes the October 21 final approval hearing as upcoming or the settlement as only preliminarily approved.
Independently fact-checked against the cited primary sources
Governing law re-checked for recent changes
The Law Behind This Article
This article rests on the statutory provisions below, held in our own legal record and retrieved from the official source. Tap a section to read the operative text.
United States Code Title 28
§ 1407Multidistrict litigationIn forcecited in 2 of our articles
When civil actions involving one or more common questions of fact are pending in different districts, such actions may be transferred to any district for coordinated or consolidated pretrial proceedings. Such transfers shall be made by the judicial panel on multidistrict litigation authorized by this section upon its determination that transfers for such proceedings will be for the convenience of parties and witnesses and will promote the just and efficient conduct of such actions. Each action so transferred shall be remanded by the panel at or before the conclusion of such pretrial proceedings to the district from which it was transferred unless it shall have been previously terminated: Provided, however, That the panel may separate any claim, cross-claim, counter-claim, or third-party claim and remand any of such claims before the remainder of the action is remanded. Such coordinated or consolidated pretrial proceedings shall be conducted by a judge or judges to whom such actions are assigned by the judicial panel on multidistrict litigation.
Official text (excerpt) · last checked 2026-09-14 · Read the full text in our law library · Verify at uscode.house.gov
Cited in 4,842 court opinions in our collectionLatest citing opinion in our collection: 2026
Opinions citing this section in our collection:
- In Re Phenylpropanolamine (Ppa) Products Liability Litigation, Shantell Allen, on Behalf of Allen, Vera v. Bayer Corporation, Leon Anderson, Jr. v. Bayer Corporation, Leslie Ackel v. Bayer Corporation, Bridgett Arrington v. Bayer Corporation, Calvin McGriggs v. Delaco Company, Betty Clinton v. Delaco Company, Donna Sasseen v. Ide Interstate Inc., Elizabeth Page v. Bayer Corporation, Marie Riley v. Wyeth, Obo Itself and Its Unincorporated Division, Wyeth Consumer Healthcare, Fka Whitehall-Robins Healthcare Formerly Known as American Home Products Corporation, and Keva K. Alford, on Behalf of All Wrongful Death Beneficiaries of Henry Dexter, and Eddie Bullock v. Wyeth, Obo Itself and Its Unincorporated Division, Wyeth Consumer Healthcare, Fka Whitehall-Robins Healthcare Formerly Known as American Home Products Corporation, and Novartis Pharmaceuticals Corporation, Bobby Holmes v. Bayer Corporation, Melody McDaniel v. Wal-Mart Stores, Inc., Samantha Samuels v. Bayer Corporation (Court of Appeals for the Ninth Circuit 2006, 460 F.3d 1217)“…to promote the just and efficient conduct of the actions. 28 U.S.C. § 1407 . As a result, the considerations that…”
- Illinois Brick Co. v. Illinois (Supreme Court of the United States 1977, 431 U.S. 720)“…cedural devices, such as the Multidistrict Litigation Act, 28 U. S. C. § 1407 , and statutory interpleader, 28 U. S.…”
- Sprint Communications Co. v. APCC Services, Inc. (Supreme Court of the United States 2008, 554 U.S. 269)“…idation of related cases filed in the same district court); 28 U. S. C. §1407 (authorizing consolidation of pretrial…”
Identified automatically from the court opinions citing this section — not a ranking of which case controls.
Also relied on in: AT&T Settlement MDL Reassigned in August 2026; Final Approval Granted October 2
Sources and References
- U.S. Judicial Panel on Multidistrict Litigation (how MDLs are created)(uscourts.gov).gov
- U.S. Courts, Multidistrict Litigation overview(uscourts.gov).gov
- JPML, pending MDLs list(uscourts.gov).gov
- 28 U.S.C. 1407 (the MDL statute)(law.cornell.edu)
- JPML, MDL Statistics Report, Docket Summary Listing (Sept. 1, 2026), listing MDL 3191 (Non-AFFF Firefighter Turnout Gear, D. Minn.)(uscourts.gov).gov
- W.D. Pa., In re Philips Recalled CPAP (MDL 3014), Order Granting Final Approval of Medical Monitoring Class Settlement (Dec. 5, 2024)(uscourts.gov).gov
- Weed Killer Settlement, official court-appointed administrator site (settlement status and claim availability)(weedkillerclass.com)
- MassDevice, jury returns $88 million verdict in first Covidien hernia mesh bellwether (Aug. 2026)(massdevice.com)
- JPML, Distribution of Pending MDL Dockets by Actions Pending (September 1, 2026)(uscourts.gov).gov
- California Attorney General, $17 billion multistate settlement with Meta (August 26, 2026)(oag.ca.gov).gov
- In re Depo-Provera, MDL 3140 (N.D. Fla.), Case Management Order No. 13 appointing a settlement administrator (Aug. 5, 2026)(uscourts.gov).gov
- In re Camp Lejeune Water Litigation, No. 7:23-cv-897 (E.D.N.C.), Order Regarding Reappointment of Plaintiffs' Leadership Group (June 30, 2026)(camplejeunecourtinfo.com)
- In re Valsartan, Losartan, and Irbesartan Prods. Liab. Litig., MDL 2875 (D.N.J.), economic loss class settlement long form notice(sartanmedicationsettlement.com)
- AbbVie Inc., Form 10-Q for the quarter ended June 30, 2026 (BIOCELL and ALCL litigation)(sec.gov).gov
- Abbott, agreements resolving a portion of the preterm infant formula litigation (August 20, 2026)(abbott.mediaroom.com)
- Alabama Attorney General, $12.2 million settlement with Roblox (April 21, 2026)(alabamaag.gov).gov
- West Virginia Attorney General, settlement with Roblox (April 21, 2026)(ago.wv.gov).gov
- Combat Arms Earplug Settlement Program, official administrator site (funding schedule and payments issued)(combatarmssettlement.com)
- JPML, In re Future Motion, Inc. Products Liability Litigation, MDL No. 3087, Transfer Order (Dec. 8, 2023), centralizing the Onewheel actions in N.D. Cal. before Judge Beth Labson Freeman(uscourts.gov).gov
- JPML, In re Tasigna (Nilotinib) Products Liability Litigation, MDL No. 3006, Transfer Order (Aug. 10, 2021), centralizing the Tasigna actions in M.D. Fla. before Judge Roy B. Dalton(uscourts.gov).gov
- Defendants-Appellees' Petition for Rehearing or Rehearing En Banc, In re Acetaminophen - ASD/ADHD Products Liability Litigation, Nos. 24-916(L) et al. (2d Cir., filed Sept. 2026)(aboutlawsuits.com)
- JPML, In re Taxotere (Docetaxel) Eye Injury Products Liability Litigation, MDL No. 3023, Transfer Order (Feb. 1, 2022)(jpml.uscourts.gov).gov
- Becton, Dickinson and Company, Form 10-Q for the quarter ended June 30, 2026 (filed Aug. 6, 2026), Note 6 Contingencies(sec.gov).gov
- Consent Judgment, People of the State of California v. Meta Platforms, Inc., No. 4:23-cv-05448 (N.D. Cal. Aug. 26, 2026)(courtlistener.com)
- U.S. District Court, E.D. Pa., MDL 3163 (GLP-1 RAs NAION) orders, including Case Management Order No. 12 (July 2, 2026)(paed.uscourts.gov).gov
- Transcript of Pretrial Conference, E.D.N.C. Camp Lejeune litigation (Sept. 9, 2026)(camplejeunecourtinfo.com)
- GSK plc, Form 6-K (filed Sept. 8, 2026), Zantac litigation update(sec.gov).gov
- Docket, Inman v. Mead Johnson & Company, LLC, No. 1:22-cv-03737 (N.D. Ill.), entries 249 to 251(courtlistener.com)
- Docket, In re Future Motion, Inc. Products Liability Litigation, No. 5:23-md-03087 (N.D. Cal.)(courtlistener.com)
- U.S. District Court, N.D. Fla., In re Depo-Provera Products Liability Litigation, MDL 3140, case management orders by date(flnd.uscourts.gov).gov
- In re Depo-Provera (Depot Medroxyprogesterone Acetate) Prods. Liab. Litig., MDL No. 3140 (N.D. Fla.), Case Management Order No. 12 (July 27, 2026), recording the parties' representation that settlement registration should be completed in November 2026 with payments beginning to roll out by the first quarter of 2027(uscourts.gov).gov
- Teva Pharmaceutical Industries Limited, Form 10-Q for the period ended June 30, 2026, commitments and contingencies note stating that the first Georgia MDL Paragard bellwether trial concluded on February 3, 2026 with a defense verdict and that in July 2026 the court entered an order scheduling the second bellwether trial to begin April 12, 2027(sec.gov).gov
- Judicial Panel on Multidistrict Litigation, Transfer Order creating In re: Recalled Abbott Infant Formula Products Liability Litigation, MDL No. 3037 (filed Aug. 5, 2022), centralizing the actions in the Northern District of Illinois before Judge Matthew F. Kennelly(uscourts.gov).gov
- Roblox Corporation, Form 10-Q for the quarterly period ended June 30, 2026 (filed July 30, 2026), commitments and contingencies note stating that the company had entered into settlement agreements with states including Alabama, Mississippi, Nevada, South Dakota and West Virginia as of July 30, 2026, that it accrued $34 million and $91 million of expense for the three and six months ended June 30, 2026 for settlement agreements and settlement discussions, and that states which had filed suit as of that date include Arkansas, Florida, Indiana, Iowa, Kentucky, Louisiana, Nebraska, Oklahoma, Tennessee and Texas, plus Los Angeles County, California(sec.gov).gov
- JPML, MDL Statistics Report, Distribution of Pending MDL Dockets by District (Sept. 1, 2026), the source for the pending and total action counts on MDL 2243, 3036, 3040, 3050, 3051, 3052, 3078 and 3081(uscourts.gov).gov
- JPML, Distribution of Pending MDL Dockets by Actions Pending (June 1, 2026), showing MDL 3036 (Gardasil) with 129 actions pending before the drop to 6(uscourts.gov).gov
- JPML, In re Fosamax (Alendronate Sodium) Products Liability Litigation (No. II), MDL No. 2243, transfer order, describing claims that Fosamax or its generic equivalent causes femur fractures or similar bone injuries, centralized in the District of New Jersey(uscourts.gov).gov
- JPML, In re Chantix (Varenicline) Marketing, Sales Practices and Products Liability Litigation (No. II), MDL No. 3050, Transfer Order (Dec. 2022), describing Pfizer's 2021 recall of Chantix over the nitrosamine impurity N-nitroso-varenicline, a probable human carcinogen, and centralizing the putative class actions in the Southern District of New York(uscourts.gov).gov
- In re Gardasil Products Liability Litigation, No. 24-1828 (4th Cir. Sept. 4, 2025) (published), affirming dismissal because the plaintiffs had to exhaust the Vaccine Act's Court of Federal Claims petition process before suing Merck(uscourts.gov).gov
- JPML, In re Kia Hyundai Vehicle Theft Marketing, Sales Practices, and Products Liability Litigation, MDL No. 3052, transfer order, describing 2011 to 2022 Kia and 2015 to 2022 Hyundai vehicles with insert-and-turn steel key ignitions alleged to lack engine immobilizer technology, centralized in the Central District of California(uscourts.gov).gov
- JPML, In re ARC Airbag Inflators Products Liability Litigation, MDL No. 3051, Transfer Order (Dec. 2022), describing allegations that ARC airbag inflators can rupture and disperse shrapnel and that the recalls issued to date are inadequate, centralized in the Northern District of Georgia(uscourts.gov).gov
- JPML, In re Chrysler Pacifica Fire Recall Products Liability Litigation, MDL No. 3040, Initial Transfer Order (July 2022), describing model year 2017 and 2018 Pacifica Plug-In Hybrid vehicles alleged to be prone to fire and a February 11, 2022 recall notice alleged to be inadequate, centralized in the Eastern District of Michigan(uscourts.gov).gov
- Generac Holdings Inc., Form 10-Q for the quarter ended June 30, 2026, reporting that the parties in In re Generac Solar Power Systems (MDL No. 23-md-3078, E.D. Wis.) obtained preliminary approval of a classwide settlement, that final approval will be sought, and that Generac reserved for a $15 million settlement fund(sec.gov).gov
- Docket, Divelbliss v. Bard Access Systems, Inc., No. 2:23-cv-01627 (D. Ariz.), entry 39 (Judgment, filed Sept. 10, 2026)(courtlistener.com)
- MDL 3047 (N.D. Cal.) docket: Order Regarding Pretrial Schedule (Tucson and Charleston), Dkt. 3542, filed Oct 1, 2026 (school-district bellwethers; first pretrial conference Nov 13, 2026; trial Feb 8, 2027)(www.courtlistener.com)
- MDL 3084 (N.D. Cal.) docket: Dkt. 7396, Sept 15, 2026, setting the Jane Doe QLF 001 trial to begin Oct 5, 2026(www.courtlistener.com)
- Official ARB economic-loss settlement administrator: Final Approval Orders of July 6, 2026, MDL 2875 (D.N.J.), Docs. 3339 (Aurobindo-Irbesartan), 3341 (Hetero-Valsartan) and 3342 (Vivimed-Losartan)(sartanmedicationsettlement.com)
- Supreme Court of the United States: Needham v. Merck & Co., No. 25-924, petition for certiorari denied March 30, 2026(www.supremecourt.gov).gov
- Camp Lejeune CLJA litigation, E.D.N.C.: Joint Status Report, Doc. 926, filed Oct 2, 2026 (Sept 16, 2026 reset of the Mousser and Fancher trial dates)(camplejeunecourtinfo.com)
- U.S. District Court, N.D. Fla.: In re Depo-Provera, MDL No. 3140, Case Management Order No. 14, Doc. 738, filed Aug 10, 2026 (Nov 30, 2026 registration deadline)(www.flnd.uscourts.gov).gov
- U.S. Judicial Panel on Multidistrict Litigation: In re Abbott Laboratories Spinal Cord Stimulator Products Liability Litigation, MDL No. 3194, Transfer Order, Doc. 54, filed Oct. 2, 2026 (N.D. Ill., Judge Lindsay C. Jenkins)(uscourts.gov).gov
- U.S. Judicial Panel on Multidistrict Litigation: In re Nevro Corporation Spinal Cord Stimulator Products Liability Litigation, MDL No. 3195, Transfer Order, Doc. 44, filed Oct. 2, 2026 (N.D. Cal., Judge Haywood S. Gilliam Jr.)(uscourts.gov).gov
- U.S. Judicial Panel on Multidistrict Litigation: In re Apple AirTag Marketing, Sales Practices, and Products Liability Litigation, MDL No. 3199, Transfer Order, Doc. 78, filed Oct. 2, 2026 (N.D. Cal., Judge Noël Wise)(uscourts.gov).gov
- In re Generac Solar Power Systems Marketing, Sales Practices and Products Liability Litigation, MDL No. 3078, official court-approved settlement website FAQ: final approval hearing set for October 21, 2026 at 10:00 a.m. CDT before Judge Lynn Adelman (E.D. Wis.), $15,000,000 settlement fund, claim deadline August 24, 2026(generacsnapsettlement.com)
- Second Amended Case Management Order No. 15 (Bellwether Protocol), In re Suboxone Film Prods. Liab. Litig., MDL No. 3092 (N.D. Ohio Mar. 27, 2026), Doc. 668(ohnd.uscourts.gov).gov
- Case Management Order No. 42, In re Bard Implanted Port Catheter Prods. Liab. Litig., MDL No. 3081 (D. Ariz.), Doc. 6388 (bellwether trial schedule)(azd.uscourts.gov).gov
- Order Aiding Private Settlement, In re Fosamax Litigation, Docket No. MID-L-9598-14 (N.J. Super. Ct. Aug. 13, 2025)(njcourts.gov).gov
- Merck & Co. Form 10-Q for the quarter ended June 30, 2026 (Gardasil product liability settlement now final)(sec.gov).gov
- MDL No. 3084 (N.D. Cal.) docket entries on bellwether replenishment: Dkt. 7813, letter from counsel for Uber (Oct. 14, 2026), and Dkt. 7839, plaintiffs’ response (Oct. 15, 2026)(uscourts.gov).gov
- JPML, MDL Statistics Report, Distribution of Pending MDL Dockets by Actions Pending (Oct. 1, 2026), showing MDL 2848 (Zostavax) with 0 of 2,664 actions pending, and MDL 2768 (Stryker LFIT V40) with 47 of 1,240, MDL 2905 (ZF-TRW airbag control units) with 28 of 28 and MDL 2841 (MONAT hair care) with 13 of 13 actions pending(uscourts.gov).gov
- JPML, MDL Statistics Report, Distribution of Pending MDL Dockets by Actions Pending (July 1, 2026), showing MDL 2848 (Zostavax) with 826 of 2,665 actions pending before the wind-down(uscourts.gov).gov
- JPML, MDL Statistics Report, Docket Summary Listing (Oct. 1, 2026), listing MDL 3015 (J&J Sunscreen, S.D. Fla., Judge Raag Singhal, master docket 0:21-md-3015, transferred Oct. 8, 2021) among active litigations with no closing date(uscourts.gov).gov
- In re Johnson & Johnson Aerosol Sunscreen Marketing, Sales Practices and Products Liability Litigation, Nos. 23-11319 & 23-11541 (11th Cir. June 20, 2024) (per curiam), vacating approval of the class settlement and remanding to apply Drazen v. Pinto and to examine standing for injunctive relief(uscourts.gov).gov
- Order denying the petition for panel rehearing or rehearing en banc, Rutledge v. Walgreen Co., Nos. 24-916(L), 24-1121(Con), 24-2360(Con), 24-2594 (2d Cir. Oct. 16, 2026), DktEntry 320.1 (copy of the signed clerk's order)(uschamber.com)
- JPML, In re Stryker LFIT V40 Femoral Head Products Liability Litigation, MDL No. 2768, Initial Transfer Order (Apr. 5, 2017), describing the August 29, 2016 voluntary recall of lots manufactured before March 2011 over failure of the femoral head to lock onto the stem at the taper junction ("taper lock failure") and alleged corrosion at that junction, centralized in the District of Massachusetts before Judge Indira Talwani(uscourts.gov).gov
- JPML, In re MONAT Hair Care Products Marketing, Sales Practices and Products Liability Litigation, MDL No. 2841, Initial Transfer Order (June 6, 2018), describing allegations that Monat advertised its products as promoting hair stability and growth while users experienced significant hair loss or thinning, itching, scalp irritation, sores and cystic acne, centralized in the Southern District of Florida before Judge Darrin P. Gayles(uscourts.gov).gov
- JPML, In re ZF-TRW Airbag Control Units Products Liability Litigation, MDL No. 2905, Initial Transfer Order (Aug. 2019), describing allegations that an electrical overstress condition can cause a malfunction of the airbag control unit’s application specific integrated circuit so that the airbag could fail to deploy in an accident, centralized in the Central District of California(uscourts.gov).gov
- Order and Judgment Granting Plaintiffs’ Unopposed Motion for Final Approval of Class Action Settlement (signed Oct. 22, 2026), In re Generac Solar Power Systems MDL No. 3078 (E.D. Wis.), court documents page, official settlement administrator site(generacsnapsettlement.com)
- Bayer, Monsanto unanimously wins first Roundup trial since U.S. Supreme Court decision (news release, St. Louis, Oct. 29, 2026), reporting the unanimous defense verdict in Theresa Aretino, et al. v. Monsanto Company(bayer.com)